[{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"a01c1d5f-e2a9-42b3-82b6-70a6e6b04112","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT02883049","created_at":"2021-01-18T14:09:12.849Z","updated_at":"2025-02-25T13:39:22.892Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","source_id_and_acronym":"NCT02883049 - AALL1131","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5949","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-21"},{"id":"39a3ce34-fc3f-4772-a312-5b10b9a2eacf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00390793","created_at":"2022-04-24T08:54:27.800Z","updated_at":"2025-02-25T14:06:37.175Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","source_id_and_acronym":"NCT00390793","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 09/28/2006","start_date":" 09/28/2006","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2025-02-17"},{"id":"0adc2fbc-6b3e-4f34-8de8-ac2947fe1dfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070499","created_at":"2021-01-18T00:10:44.565Z","updated_at":"2025-02-25T16:21:43.510Z","phase":"Phase 2","brief_title":"Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00070499","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 406","initiation":"Initiation: 08/15/2004","start_date":" 08/15/2004","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2024-12-27"},{"id":"4d2a06b2-d858-435f-8f2c-4ebc80c32731","acronym":"","url":"https://clinicaltrials.gov/study/NCT00254423","created_at":"2021-01-18T00:51:48.619Z","updated_at":"2024-07-02T16:34:26.966Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00254423","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • IFNA1","pipe":"","alterations":" ","tags":["ABL1 • BCR • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 11/08/2005","start_date":" 11/08/2005","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-06-12"},{"id":"d089607a-1031-4001-af05-f61c61e55845","acronym":"","url":"https://clinicaltrials.gov/study/NCT02013648","created_at":"2021-01-18T09:12:24.696Z","updated_at":"2024-07-02T16:35:17.930Z","phase":"Phase 3","brief_title":"Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)","source_id_and_acronym":"NCT02013648","lead_sponsor":"University of Ulm","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-23"},{"id":"7ad2d769-2235-480c-af61-d1fa70b9f998","acronym":"","url":"https://clinicaltrials.gov/study/NCT00255346","created_at":"2021-01-18T00:51:58.980Z","updated_at":"2025-02-25T14:23:55.411Z","phase":"Phase 2","brief_title":"Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)","source_id_and_acronym":"NCT00255346","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 11/15/2005","start_date":" 11/15/2005","primary_txt":" Primary completion: 03/03/2017","primary_completion_date":" 03/03/2017","study_txt":" Completion: 03/03/2017","study_completion_date":" 03/03/2017","last_update_posted":"2023-12-18"},{"id":"d4088676-34af-47b3-9b35-79e3fba11bee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03193281","created_at":"2021-01-18T15:44:28.970Z","updated_at":"2024-07-02T16:35:27.695Z","phase":"Phase 2","brief_title":"KISS Study: Kinase Inhibition With Sprycel Start up","source_id_and_acronym":"NCT03193281","lead_sponsor":"University of Auckland, New Zealand","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-29"},{"id":"13942605-9bf5-41a2-a7c2-5c5e7a8f8689","acronym":"","url":"https://clinicaltrials.gov/study/NCT03625388","created_at":"2021-01-18T17:48:36.247Z","updated_at":"2024-07-02T16:35:36.010Z","phase":"Phase 2","brief_title":"Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","source_id_and_acronym":"NCT03625388","lead_sponsor":"Hikma Pharmaceuticals LLC","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 11/05/2018","start_date":" 11/05/2018","primary_txt":" Primary completion: 07/22/2023","primary_completion_date":" 07/22/2023","study_txt":" Completion: 07/22/2023","study_completion_date":" 07/22/2023","last_update_posted":"2023-09-22"},{"id":"ec9ebcd5-07dc-44c4-84f3-b2f26c471cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT00777036","created_at":"2022-04-24T08:54:50.612Z","updated_at":"2024-07-02T16:35:37.250Z","phase":"Phase 2","brief_title":"A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib","source_id_and_acronym":"NCT00777036","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 03/20/2009","start_date":" 03/20/2009","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 12/07/2029","study_completion_date":" 12/07/2029","last_update_posted":"2023-09-13"},{"id":"dcd9e53d-f4f0-4adb-850a-ee80175c02da","acronym":"","url":"https://clinicaltrials.gov/study/NCT04180371","created_at":"2021-01-20T21:59:42.169Z","updated_at":"2024-07-02T16:35:42.863Z","phase":"Phase 1/2","brief_title":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","source_id_and_acronym":"NCT04180371","lead_sponsor":"BicycleTx Limited","biomarkers":" CD4 • EPHA2","pipe":"","alterations":" ","tags":["CD4 • EPHA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • nuzefatide pevedotin (BT5528)"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 11/07/2019","start_date":" 11/07/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-17"},{"id":"b23fd882-ff28-4564-bc15-fe532fcc31ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00700882","created_at":"2021-01-17T17:21:43.588Z","updated_at":"2024-07-02T16:35:44.187Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00700882","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT positive • KIT amplification","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive • KIT amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 07/02/2009","start_date":" 07/02/2009","primary_txt":" Primary completion: 05/06/2016","primary_completion_date":" 05/06/2016","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2023-06-30"},{"id":"d04e0b2e-50d8-4bda-a7cf-087faf85938c","acronym":"DASCERN","url":"https://clinicaltrials.gov/study/NCT01593254","created_at":"2022-04-24T08:55:47.439Z","updated_at":"2024-07-02T16:35:45.286Z","phase":"Phase 2b","brief_title":"Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib","source_id_and_acronym":"NCT01593254 - DASCERN","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Completed","enrollment":" Enrollment 262","initiation":"Initiation: 09/12/2012","start_date":" 09/12/2012","primary_txt":" Primary completion: 11/08/2017","primary_completion_date":" 11/08/2017","study_txt":" Completion: 04/12/2022","study_completion_date":" 04/12/2022","last_update_posted":"2023-06-22"},{"id":"d94efaf1-e651-4f75-b178-3ccd46b27720","acronym":"DasaHIT","url":"https://clinicaltrials.gov/study/NCT02890784","created_at":"2022-04-24T08:57:55.150Z","updated_at":"2024-07-02T16:35:48.419Z","phase":"Phase 3","brief_title":"Dasatinib Holiday for Improved Tolerability","source_id_and_acronym":"NCT02890784 - DasaHIT","lead_sponsor":"University of Jena","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 291","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-05-10"},{"id":"344dd84f-cbb2-4195-9057-7e6bb67aba39","acronym":"","url":"https://clinicaltrials.gov/study/NCT01238211","created_at":"2021-01-18T04:59:02.957Z","updated_at":"2024-07-02T16:35:54.402Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01238211","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 12/14/2010","start_date":" 12/14/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 03/15/2021","study_completion_date":" 03/15/2021","last_update_posted":"2023-03-01"},{"id":"ed788d65-0132-4f88-b51e-b0cbc192fc90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638763","created_at":"2022-12-06T15:57:59.939Z","updated_at":"2024-07-02T16:35:59.603Z","phase":"Phase 2","brief_title":"Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT05638763","lead_sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2022-12-06"},{"id":"e7033896-fcec-418f-8e4b-f86692adf22f","acronym":"DASFREE","url":"https://clinicaltrials.gov/study/NCT01850004","created_at":"2022-04-24T08:56:18.989Z","updated_at":"2024-07-02T16:36:01.073Z","phase":"Phase 2","brief_title":"Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response","source_id_and_acronym":"NCT01850004 - DASFREE","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 01/22/2014","start_date":" 01/22/2014","primary_txt":" Primary completion: 09/20/2017","primary_completion_date":" 09/20/2017","study_txt":" Completion: 10/08/2021","study_completion_date":" 10/08/2021","last_update_posted":"2022-11-03"},{"id":"c81e0450-f009-4d86-a65d-1c4989fa8acc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04155411","created_at":"2021-01-18T20:15:08.649Z","updated_at":"2024-07-02T16:36:06.577Z","phase":"Phase 4","brief_title":"Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP","source_id_and_acronym":"NCT04155411","lead_sponsor":"Shenzhen Second People's Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-07-27"},{"id":"a25a7657-8064-40e7-806c-f6d355167a9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05042531","created_at":"2021-09-13T14:55:55.634Z","updated_at":"2024-07-02T16:36:11.575Z","phase":"","brief_title":"Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia","source_id_and_acronym":"NCT05042531","lead_sponsor":"LanZhou University","biomarkers":" TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A","pipe":"","alterations":" ","tags":["TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/13/2021","start_date":" 11/13/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-04-25"},{"id":"cc62689a-9210-4497-9d99-6a97e2c2429c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00566618","created_at":"2021-01-18T02:04:00.307Z","updated_at":"2025-02-25T14:25:22.607Z","phase":"Phase 1/2","brief_title":"Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis","source_id_and_acronym":"NCT00566618","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 11/17/2020","primary_completion_date":" 11/17/2020","study_txt":" Completion: 11/17/2020","study_completion_date":" 11/17/2020","last_update_posted":"2022-02-25"},{"id":"ae93fc49-7334-4ba2-a110-e4536203781b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01724879","created_at":"2021-01-17T17:29:42.145Z","updated_at":"2024-07-02T16:36:18.004Z","phase":"Phase 2","brief_title":"Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)","source_id_and_acronym":"NCT01724879","lead_sponsor":"Goethe University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • cyclophosphamide • vindesine"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2015","study_completion_date":" 09/01/2015","last_update_posted":"2022-01-26"},{"id":"41bf46eb-4e69-4dd6-b089-ef2edecd72da","acronym":"CML1113","url":"https://clinicaltrials.gov/study/NCT01761890","created_at":"2022-04-24T08:56:10.942Z","updated_at":"2024-07-02T16:36:18.849Z","phase":"","brief_title":"Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib","source_id_and_acronym":"NCT01761890 - CML1113","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 01/28/2014","start_date":" 01/28/2014","primary_txt":" Primary completion: 12/02/2018","primary_completion_date":" 12/02/2018","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-01-05"},{"id":"45803419-bac2-411b-954d-b04c61dbdb9a","acronym":"AALL1122","url":"https://clinicaltrials.gov/study/NCT01460160","created_at":"2022-04-24T08:55:37.426Z","updated_at":"2024-07-02T16:36:19.717Z","phase":"Phase 2","brief_title":"Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01460160 - AALL1122","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 04/13/2012","start_date":" 04/13/2012","primary_txt":" Primary completion: 05/28/2017","primary_completion_date":" 05/28/2017","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2021-12-08"},{"id":"d2a455dd-cf23-4cbb-9688-13b71213d425","acronym":"","url":"https://clinicaltrials.gov/study/NCT04925141","created_at":"2021-06-14T18:52:37.952Z","updated_at":"2024-07-02T16:36:29.135Z","phase":"Phase 4","brief_title":"A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)","source_id_and_acronym":"NCT04925141","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" BCR","pipe":"","alterations":" ","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 05/10/2016","start_date":" 05/10/2016","primary_txt":" Primary completion: 10/22/2018","primary_completion_date":" 10/22/2018","study_txt":" Completion: 12/06/2019","study_completion_date":" 12/06/2019","last_update_posted":"2021-06-14"}]